CBD-Tacrolimus interaction study completed: key dosing insights revealed
NCT ID NCT05490511
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study looked at how cannabidiol (CBD) interacts with tacrolimus, a drug used to prevent organ rejection in transplant patients. Researchers measured drug levels in 57 healthy adults and those with chronic kidney disease to understand how genetics and CBD affect dosing. The goal is to help doctors adjust doses for better long-term transplant success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IU Health University Hospital
Indianapolis, Indiana, 46202, United States
Conditions
Explore the condition pages connected to this study.